Saruparib in HRDsig+ Solid Tumors
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Study ID
- NCT07832630
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Malignant Neoplastic Disease (Disorder)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Saruparib — DRUGSaruparib (AZD5305) 60mg PO daily
- FoundationOne®CDx — DIAGNOSTIC_TESTTumors will be tested for positive HRDsig tumor by the investigational FoundationOne®CDx clinical trial assay.
Study Details
The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational FoundationOne®CDx clinical trial assay.
Key Dates
- First listed
- Sep 22, 2026
- Start date
- Nov 1, 2026
- Status verified
- Sep 2026
- Primary completion
- Nov 1, 2029
- Completion
- Nov 1, 2030
Study Design
- Enrollment
- 124 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Saruparib (AZD5305)Saruparib
Primary Outcome Measure
Best objective response as determined by RECIST v.1.1 [ Time Frame: From baseline through documented disease progression (RECIST v1.1) or death from any cause, whichever occurs first, up to 2 years. ]
Central Contacts
- Kim Reiss Binder, MD215-360-0735
- Alex Torres267-496-7621
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Kim Reiss Binder, MD (PRINCIPAL_INVESTIGATOR) |